ArticleNeuropsychiatric disease and treatment2025
Antidepressant Effect of Short-Chain Fatty Acids on Chronic Unpredictable Mild Stress in Model Rats And Their Influence on the Oral-Gut Microbiota.
Article in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the effects of short-chain fatty acids (SCFAs) on depression-like behaviors and the oral gut microbiota in rats subjected to chronic unpredictable mild stress (CUMS) using behavioral tests and high-throughput sequencing of 16SrRNA. Methods: Sprague-Dawley rats were randomly divided into Control, CUMS, and SCFAs groups. Except for the Control group, all rats underwent CUMS modeling and drug administration for 28 days. Behavioral tests assessed depression-like behaviors, while 16SrRNA sequencing analyzed oral and gut microbiota changes. Histopathological examination of the colon tissues and immunohistochemical analysis of the tight junction protein ZO-1 were performed. Results: Interventions using SCFAs can alleviate symptoms in rats with CUMS-induced depression. Analysis of microbial diversity revealed significant differences in both Alpha and Beta diversities of the gut microbiota among all three groups. The composition of the microbiota showed that, at the phylum level, in the intestinal microbiota, the Conclusion: SCFAs intervention ameliorated depression-like behaviors, modulated gut microbiota composition, enhanced ZO-1 expression, reduced gut inflammation, and promoted immune function, thereby restoring oral gut microbiota homeostasis. This study elucidated SCFAs' therapeutic potential of SCFAs in depression and provided a theoretical foundation for their clinical application in antidepressant treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.